Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Nivolumab plus ipilimumab or relatlimab nearly doubled response rates compared to nivolumab alone in head and neck cancer.

Scolyer received a combination of anti-PD-1 (nivolumab; Opdivo, Bristol Myers Squibb), anti-CTLA-4 (ipilimumab; Yervoy, Bristol Myers Squibb) and anti-LAG3 (relatlimab; Opdualag, Bristol Myers ...

The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.

nivolumab plus ipilimumab and nivolumab plus relatlimab. Both immunotherapy combinations appeared to perform equally well. The researchers attribute this to the drugs activating tumor-specific T ...

nivolumab plus ipilimumab and nivolumab plus relatlimab. Both immunotherapy combinations appeared to perform equally well. The researchers attribute this to the drugs activating tumor-specific T ...

Seven-year follow-up data of a multicenter, randomized phase 2 study evaluating the treatment of melanoma brain metastases shows ipilimumab plus nivolumab is an effective long-term care option.

360 HLA-A*02:01-positive patients will be randomized 1:1 to treatment with IMA203 or investigator’s choice of selected approved treatments in the 2L setting (nivolumab/relatlimab, nivolumab ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab – was unable to improve on Opdivo alone in the RELATIVITY-098 ...

360 HLA-A*02:01-positive patients will be randomized 1:1 to treatment with IMA203 or investigator's choice of selected approved treatments in the 2L setting (nivolumab/relatlimab, nivolumab, ...

The DEPEND study evaluated nivolumab as a neoadjuvant immunotherapy in human papilloma virus-negative locoregionally advanced head and neck cancer. Nivolumab is already an FDA approved treatment ...

Options include: pembrolizumab or nivolumab nivolumab with relatlimab nivolumab or pembrolizumab, with ipilimumab About half of all people with melanoma have mutations or genetic changes in the ...

Nemvaleukin/pembrolizumab did not achieve a statistically significant improvement in OS vs investigator’s choice chemotherapy alone in the interim analysis. The ...